Additional views regarding the association between body mass index and lipoprotein(a) level in relation to atrial fibrillation

THE EDITOR Association of BMI and Lp(a) levels in AF 1 lifestyle intervention and / or recent pharmaceutical drugs (ie, glucagon -like peptide 1 -receptor agonist).Screening of Lp(a) levels has been recently advocated for cardiovascular risk stratification, and Lp(a)-targeting drugs (ie, Lp[a] inhibitors) are expected to appear in the near future.The strategy of screening and adjusting treatment based on BMI and Lp(a) levels would be useful for reducing the occurrence of AF.Therefore, the report by Guo et al, 1 showing the joint of association of elevated BMI and Lp(a) levels with the increased prevalence of AF provides valuable insights into the prevention and management of this arrhythmia.